Literature DB >> 18584413

Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.

Antje Schubert1, Hiltrud Schulz, Günter Emons, Carsten Gründker.   

Abstract

BACKGROUND: The majority of human breast cancers and in addition most breast-cancer cell lines express gonadotropin-releasing hormone (GnRH) receptors. Their proliferation and in addition their bone-directed invasion is time- and dose-dependently reduced by GnRH. Osteolytic metastases are characteristic for breast cancer-derived metastasis. Since the osteolytic activity depends on the receptor activator of nuclear factor-kappaB (NFkappaB) ligand (RANKL)/osteoprotegerin (OPG) ratio, we analyzed RANKL and OPG expression in different breast-cancer cell lines.
METHODS: Different human breast-cancer cell lines were tested for expression of GnRH receptor, OPG and RANKL. Using a co-culture system of breast-cancer cell lines and human primary osteoblasts (hOB), we analyzed the expression of OPG and RANKL in the GnRH receptor-positive breast-cancer cell line HCC70 co-cultured with or without hOB. In addition, we assessed the effects of GnRH analog treatment on OPG and RANKL mRNA and protein levels.
RESULTS: All tested breast-cancer cell lines were GnRH receptor-positive. The majority of these cell lines expressed OPG but not RANKL. The HCC70 breast-cancer cell line derived from an invasive ductal carcinoma with metastases was positive for both OPG and RANKL. The expression of RANKL by HCC70 cells was increased when co-cultured with hOB. Treatment with GnRH analogs reduced the expression of RANKL by HCC70 cells co-cultured with hOB. No effects were observed on breast cancer OPG expression.
CONCLUSIONS: These data show that the majority of human breast-cancer cell lines express OPG but not RANKL. The HCC70 breast-cancer cell line is RANKL-positive. Co-culture of HCC70 breast cancer cells with hOB increases RANKL expression. Activation of tumor GnRH receptors reduces RANKL expression. These experiments demonstrate that HCC70 breast cancer cells are able to activate osteoclasts directly via RANKL. The interaction between HCC70 breast cancer cells and osteoblasts induces osteoclastogenesis through an increase of RANKL expression. GnRH seems to play an important role by modulating the RANKL expression in HCC70 breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18584413     DOI: 10.1080/09513590802095845

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  8 in total

1.  Butein, a tetrahydroxychalcone, suppresses cancer-induced osteoclastogenesis through inhibition of receptor activator of nuclear factor-kappaB ligand signaling.

Authors:  Bokyung Sung; Sung-Gook Cho; Mingyao Liu; Bharat B Aggarwal
Journal:  Int J Cancer       Date:  2011-03-11       Impact factor: 7.396

2.  The association between RANKL and Osteoprotegerin gene polymorphisms with breast cancer.

Authors:  Heba S Omar; Olfat G Shaker; Yasser H Nassar; Samar A Marzouk; Mohamed S ElMarzouky
Journal:  Mol Cell Biochem       Date:  2015-02-28       Impact factor: 3.396

3.  Breast cancer at bone metastatic sites: recent discoveries and treatment targets.

Authors:  Osama Hussein; Svetlana V Komarova
Journal:  J Cell Commun Signal       Date:  2011-01-19       Impact factor: 5.782

4.  RANK, RANKL and OPG Expression in Breast Cancer - Influence on Osseous Metastasis.

Authors:  J T Ney; T Fehm; I Juhasz-Boess; E F Solomayer
Journal:  Geburtshilfe Frauenheilkd       Date:  2012-05       Impact factor: 2.915

5.  Association analyses suggest the effects of RANK and RANKL on age at menarche in Chinese women.

Authors:  R Pan; Y-Z Liu; H-W Deng; V Dvornyk
Journal:  Climacteric       Date:  2011-10-24       Impact factor: 3.005

6.  Inferring gene dependency network specific to phenotypic alteration based on gene expression data and clinical information of breast cancer.

Authors:  Xionghui Zhou; Juan Liu
Journal:  PLoS One       Date:  2014-03-17       Impact factor: 3.240

7.  Gene polymorphisms in RANKL/RANK/OPG pathway are associated with ages at menarche and natural menopause in Chinese women.

Authors:  Peng Duan; Zhi-Ming Wang; Jiang Liu; Li-Na Wang; Zhi Yang; Ping Tu
Journal:  BMC Womens Health       Date:  2015-04-13       Impact factor: 2.809

8.  Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort.

Authors:  Renée T Fortner; Danja Sarink; Helena Schock; Theron Johnson; Anne Tjønneland; Anja Olsen; Kim Overvad; Aurélie Affret; Mathilde His; Marie-Christine Boutron-Ruault; Heiner Boeing; Antonia Trichopoulou; Androniki Naska; Philippos Orfanos; Domenico Palli; Sabina Sieri; Amalia Mattiello; Rosario Tumino; Fulvio Ricceri; H Bas Bueno-de-Mesquita; Petra H M Peeters; Carla H Van Gils; Elisabete Weiderpass; Eiliv Lund; J Ramón Quirós; Antonio Agudo; Maria-José Sánchez; María-Dolores Chirlaque; Eva Ardanaz; Miren Dorronsoro; Tim Key; Kay-Tee Khaw; Sabina Rinaldi; Laure Dossus; Marc Gunter; Melissa A Merritt; Elio Riboli; Rudolf Kaaks
Journal:  BMC Med       Date:  2017-02-08       Impact factor: 8.775

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.